Fig. 1.
PILLAR study design.
FU, follow-up; PegIFN/RBV, peginterferonα-2a (180 μg/wk) + ribavirin (1000-1200 mg/day); RGT, response-guided therapy; SMV, simeprevir; W, weeks.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.